Approved HIV Drugs
Approved HIV Drugs
AIDS 2012: Changing Epidemiology of Opportunistic Infections in the ART Era
- Details
- Category: Approved HIV Drugs
- Published on Monday, 23 July 2012 00:00
- Written by Liz Highleyman
Large overall declines in opportunistic infections (OIs) among people with HIV in the U.S. mask continued high rates among inner city populations, according to a presentation Monday at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.
NRTI-sparing Atazanavir + Raltegravir: Conflicting Data for Naive and Experienced HIV Patients
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 June 2012 00:00
- Written by Liz Highleyman
A NRTI-sparing antiretroviral regimen of unboosted atazanavir (Reyataz) plus raltegravir (Isentress) suppresses HIV in treatment-naive patients as well as standard 3-drug combinations, but its twice-daily dosing, side effects, and low barrier to resistance limit its appeal. For treatment-experienced people already doing well on atazanavir triple therapy, however, the dual regimen may be an attractive simplification option.
FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children
- Details
- Category: HIV Treatment
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has approved new dosing recommendations for use of fosamprenavir (Lexiva) oral suspension for children with HIV. The agency also approved a generic nevirapine tablet for use by HIV positive children in PEPFAR countries.
Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 30 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) recently approved new product label information for raltegravir (Isentress), adding longer-term data showing that the drug remains effective for more than 3 years. In related news, researchers reported that raltegravir appears to be a good option for post-exposure prophylaxis (PEP) to prevent HIV infection.
Raltegravir (Isentress) Label Updated with New Side Effects Warning
- Details
- Category: Approved HIV Drugs
- Published on Friday, 04 November 2011 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) this week announced that the product information for the integrase inhibitor raltegravir (brand name Isentress) has been revised to include new warnings about potential skin reactions and other adverse events.
Web Design and Development by